Desferal administration to improve the impaired reaction to hypoxia in diabetes (DESIRED) - A randomised, double-blind, placebo-controlled, cross-over study.

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519562-48-00

Acronym

DESIRED

Enrollment

Registered

2025-01-13

Start date

2017-01-12

Completion date

Unknown

Last updated

2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The study will investigate the effect of deferoxamine on the impaired reaction to hypoxia in patients with diabetes mellitus type 1.

Brief summary

Number of Endothelial Precursor Cells in 10 ml blood after intermittent hypoxia exposure

Detailed description

Changes in the levels of angiogenetic chemokines (SDF-1, EPO, VEGF), Changes in the levels of angiogenetic and hypoxic induced genes (VEGFA, SDF-1, BPNP3, GLUT3, PDK1), Changes in electrophysiological parameters important for the cardiorespiratory response: R-R interval change, the standard deviation of the R-R interval, systolic and diastolic blood pressure, end-tidal carbon dioxide, arterial oxygen saturation, breathing rate, tidal volume, minute ventilation and the ratio between Vt and inspiration time (Vt/Ti), baroreflex sensitivity, arterial function parameters: pulse wave velocity, augmentation index, augmentation index corrected for heart rate (AI75)

Interventions

DRUGDesferal 500 mg pulver till injektions-/infusionsvätska

DRUGlösning

DRUGSodium chloride solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Number of Endothelial Precursor Cells in 10 ml blood after intermittent hypoxia exposure	—

Secondary

Measure	Time frame
Changes in the levels of angiogenetic chemokines (SDF-1, EPO, VEGF), Changes in the levels of angiogenetic and hypoxic induced genes (VEGFA, SDF-1, BPNP3, GLUT3, PDK1), Changes in electrophysiological parameters important for the cardiorespiratory response: R-R interval change, the standard deviation of the R-R interval, systolic and diastolic blood pressure, end-tidal carbon dioxide, arterial oxygen saturation, breathing rate, tidal volume, minute ventilation and the ratio between Vt and inspiration time (Vt/Ti), baroreflex sensitivity, arterial function parameters: pulse wave velocity, augmentation index, augmentation index corrected for heart rate (AI75)	—

Measure

Time frame

—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026